|
Alzamend Neuro, Inc. (ALZN) DCF Avaliação |
Totalmente Editável: Adapte-Se Às Suas Necessidades No Excel Ou Planilhas
Design Profissional: Modelos Confiáveis E Padrão Da Indústria
Pré-Construídos Para Uso Rápido E Eficiente
Compatível com MAC/PC, totalmente desbloqueado
Não É Necessária Experiência; Fácil De Seguir
Alzamend Neuro, Inc. (ALZN) Bundle
Procurando determinar o valor intrínseco da Alzamend Neuro, Inc.? Nossa calculadora DCF da ALZN integra dados do mundo real com opções abrangentes de personalização, permitindo refinar suas previsões e aprimorar suas estratégias de investimento.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Revenue Growth, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITDA | .0 | .0 | -12.3 | -14.8 | -9.9 | .0 | .0 | .0 | .0 | .0 |
| EBITDA, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Depreciation | 4.4 | 5.0 | .0 | .0 | .1 | .0 | .0 | .0 | .0 | .0 |
| Depreciation, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| EBIT | -4.4 | -5.0 | -12.3 | -14.9 | -9.9 | .0 | .0 | .0 | .0 | .0 |
| EBIT, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Total Cash | .1 | 1.9 | 14.1 | 5.1 | .4 | .0 | .0 | .0 | .0 | .0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .2 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Inventories | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Inventories, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Accounts Payable | .9 | .5 | 1.2 | 2.9 | 2.9 | .0 | .0 | .0 | .0 | .0 |
| Accounts Payable, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Capital Expenditure | .0 | .0 | -.1 | .0 | -.1 | .0 | .0 | .0 | .0 | .0 |
| Capital Expenditure, % | 100 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 0 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -4.4 | -5.1 | -12.4 | -14.9 | -9.9 | .0 | .0 | .0 | .0 | .0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | .7 | -.4 | -11.8 | -13.1 | -10.0 | -2.9 | .0 | .0 | .0 | .0 |
| WACC, % | 4.99 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -2.8 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 0 | |||||||||
| Terminal Value | 0 | |||||||||
| Present Terminal Value | 0 | |||||||||
| Enterprise Value | -3 | |||||||||
| Net Debt | 0 | |||||||||
| Equity Value | -3 | |||||||||
| Diluted Shares Outstanding, MM | 3 | |||||||||
| Equity Value Per Share | -0.80 |
What You Will Get
- Real Alzamend Neuro Data: Preloaded financials – from revenue to EBIT – based on actual and projected figures for Alzamend Neuro, Inc. (ALZN).
- Full Customization: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates specific to Alzamend Neuro.
- Instant Valuation Updates: Automatic recalculations to analyze the impact of changes on Alzamend Neuro’s fair value.
- Versatile Excel Template: Tailored for quick edits, scenario testing, and detailed projections for Alzamend Neuro, Inc. (ALZN).
- Time-Saving and Accurate: Skip building models from scratch while maintaining precision and flexibility for Alzamend Neuro.
Key Features
- Comprehensive DCF Calculator: Offers detailed unlevered and levered DCF valuation models tailored for Alzamend Neuro, Inc. (ALZN).
- WACC Calculator: Features a pre-built Weighted Average Cost of Capital sheet with customizable inputs specific to Alzamend Neuro, Inc. (ALZN).
- Customizable Forecast Assumptions: Adjust growth rates, capital expenditures, and discount rates to fit Alzamend Neuro, Inc. (ALZN) projections.
- Integrated Financial Ratios: Evaluate profitability, leverage, and efficiency ratios relevant to Alzamend Neuro, Inc. (ALZN).
- Interactive Dashboard and Charts: Visual representations of key valuation metrics for straightforward analysis of Alzamend Neuro, Inc. (ALZN).
How It Works
- Step 1: Download the Excel file.
- Step 2: Review pre-entered Alzamend Neuro data (historical and projected).
- Step 3: Adjust key assumptions (yellow cells) based on your analysis.
- Step 4: View automatic recalculations for Alzamend Neuro’s intrinsic value.
- Step 5: Use the outputs for investment decisions or reporting.
Why Choose This Calculator for Alzamend Neuro, Inc. (ALZN)?
- User-Friendly Interface: Tailored for both novices and seasoned professionals.
- Customizable Inputs: Adjust parameters easily to suit your financial analysis.
- Real-Time Valuation: Observe immediate updates to Alzamend Neuro’s valuation as you modify inputs.
- Preloaded Data: Comes with Alzamend Neuro’s actual financial figures for swift assessments.
- Relied Upon by Experts: Favored by investors and analysts for making well-informed choices.
Who Should Use This Product?
- Investors: Assess Alzamend Neuro’s valuation before making stock transactions.
- CFOs and Financial Analysts: Enhance valuation methodologies and evaluate financial forecasts.
- Startup Founders: Understand the valuation strategies of innovative biotech companies like Alzamend Neuro.
- Consultants: Provide comprehensive valuation analyses for clients in the healthcare sector.
- Students and Educators: Utilize real-time data to explore and teach valuation principles.
What the Template Contains
- Historical Data: Includes Alzamend Neuro’s past financials and baseline forecasts.
- DCF and Levered DCF Models: Detailed templates to calculate Alzamend Neuro’s intrinsic value.
- WACC Sheet: Pre-built calculations for Weighted Average Cost of Capital.
- Editable Inputs: Modify key drivers like growth rates, EBITDA %, and CAPEX assumptions.
- Quarterly and Annual Statements: A complete breakdown of Alzamend Neuro’s financials.
- Interactive Dashboard: Visualize valuation results and projections dynamically.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.